



Flexion Therapeutics, Inc.
 Investor Relations Department
 10 Mall Road
 Suite 301
 Burlington, MA 01803
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

| NASDAQ: FLXN | |
|---------------|--|
| Last Trade: | 23.15 |
| Trade Time: | 4:00 PM ET Oct 20, 2017 |
| Change: | -0.58 ▼ (-2.444%) |
| Day Range | 22.99 - 24.30 |
| 52-Week Range | 15.93 - 32.25 |
| Volume | 1,769,152 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 11, 2017 [Flexion Therapeutics Announces Pricing of Public Offering of Common Stock](#)
- Oct 10, 2017 [Flexion Therapeutics Announces Proposed Public Offering of Common Stock](#)
- Oct 9, 2017 [Flexion Therapeutics to Hold Conference Call at 8:00 a.m. ET to Discuss Recent FDA Approval of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\)](#)
- Oct 6, 2017 [Flexion Therapeutics Announces FDA Approval of Zilretta™ \(triamcinolone acetonide extended-release injectable suspension\) for Osteoarthritis \(OA\) Knee Pain](#)
- Sep 7, 2017 [Flexion Therapeutics to Present Data on Zilretta™ \(FX006\) at PAINWeek 2017](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 10, 2017 [Annual Report \(10-K\)](#)
- Apr 28, 2017 [Proxy Statement \(DEF 14A\)](#)
- Aug 8, 2017 [Quarterly Report \(10-Q\)](#)
- May 5, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 7, 2016 [Quarterly Report \(10-Q\)](#)